Recently Barbara Zdrazil and I published an article that explored the idea of tracking the attention being paid to a scaffold in the medicinal chemistry literature (as represented by ChEMBL). The gist of the idea is that scaffolds that are more frequently enumerated or tested in more assays (or even published in increasingly high IF […]
Byproducts of Byproducts & Biomedical Data
Recently I came across a fantastic article that explored how far ahead Google Maps is compared to Apple Maps, focusing in particular on Areas of Interest (AOI), and how this is achieved with Googles competencies in massive data and massive computation, resulting in a moat. The conclusion is that Google has gathered so much data, […]